{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T10:40:57Z","timestamp":1771584057632,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.phrs.2018.02.005","type":"journal-article","created":{"date-parts":[[2018,2,7]],"date-time":"2018-02-07T20:46:44Z","timestamp":1518036404000},"page":"244-254","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Impact of SLC22A1 and CYP3A5 genotypes on imatinib response in chronic myeloid leukemia: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"131","author":[{"given":"Sarah","family":"Cargnin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gloria","family":"Ravegnini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Soverini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"Angelini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Terrazzino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.phrs.2018.02.005_bib0005","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.phrs.2018.02.005_bib0010","doi-asserted-by":"crossref","first-page":"941","DOI":"10.2217\/pgs.13.63","article-title":"Clinical relevance of Pharmacogenetihs in gastrointestinl stromal tumor in the era of personlised therapy","volume":"14","author":"Angelini","year":"2013","journal-title":"Pharmacogenomics"},{"issue":"10","key":"10.1016\/j.phrs.2018.02.005_bib0015","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.phrs.2018.02.005_bib0020","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00062752-200401000-00006","article-title":"Mechanisms and implications of imatinib resistance mutations in BCR-ABL","volume":"11","author":"Nardi","year":"2004","journal-title":"Curr. Opin. Hematol."},{"issue":"9","key":"10.1016\/j.phrs.2018.02.005_bib0025","doi-asserted-by":"crossref","first-page":"22811","DOI":"10.3390\/ijms160922811","article-title":"Pharmacogenetics of BCR\/ABL inhibitors in chronic myeloid leukemia","volume":"16","author":"Polillo","year":"2015","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.phrs.2018.02.005_bib0030","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/tpj.2014.54","article-title":"ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis","volume":"15","author":"Zheng","year":"2015","journal-title":"Pharmacogenomics J."},{"issue":"7","key":"10.1016\/j.phrs.2018.02.005_bib0035","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1080\/17425255.2016.1184649","article-title":"Pharmacogenetics of tyrosine kinase inhibitors in gastrointestinal stromal tumor and chronic myeloid leukemia","volume":"12","author":"Ravegnini","year":"2016","journal-title":"Expert Opin. Drug. Metab. Toxicol."},{"issue":"1","key":"10.1016\/j.phrs.2018.02.005_bib0040","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2217\/pgs-2016-0103","article-title":"Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis","volume":"18","author":"Jiang","year":"2017","journal-title":"Pharmacogenomics"},{"issue":"12","key":"10.1016\/j.phrs.2018.02.005_bib0045","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","article-title":"Active transport of imatinib into and out of cells: implications for drug resistance","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.phrs.2018.02.005_bib0050","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2005-11-4687","article-title":"OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib","volume":"108","author":"White","year":"2006","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.phrs.2018.02.005_bib0055","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","article-title":"Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity","volume":"110","author":"White","year":"2007","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.phrs.2018.02.005_bib0060","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1200\/JCO.2009.26.3087","article-title":"Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib","volume":"28","author":"Marin","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.phrs.2018.02.005_bib0065","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/sj.clpt.6100268","article-title":"Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia","volume":"83","author":"Wang","year":"2008","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.phrs.2018.02.005_bib0070","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00280-017-3266-0","article-title":"hOCT1 gene expression predict for optimal response to Imatinib in Tunisian patients with chronic myeloid leukemia","volume":"79","author":"Ben Hassine","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"4","key":"10.1016\/j.phrs.2018.02.005_bib0075","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1182\/blood-2012-01-405035","article-title":"The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia","volume":"121","author":"Giannoudis","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.phrs.2018.02.005_bib0080","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/tpj.2014.7","article-title":"The c. 480C > G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia","volume":"14","author":"Di Paolo","year":"2014","journal-title":"Pharmacogenomics J."},{"issue":"11","key":"10.1016\/j.phrs.2018.02.005_bib0085","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/jhg.2010.98","article-title":"Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia","volume":"55","author":"Takahashi","year":"2010","journal-title":"J. Hum. Genet."},{"issue":"4","key":"10.1016\/j.phrs.2018.02.005_bib0090","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/ejh.12235","article-title":"OCT1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients","volume":"92","author":"Koren-Michowitz","year":"2014","journal-title":"Eur. J. Haematol."},{"issue":"14","key":"10.1016\/j.phrs.2018.02.005_bib0095","doi-asserted-by":"crossref","first-page":"4750","DOI":"10.1158\/1078-0432.CCR-09-0145","article-title":"Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia","volume":"15","author":"Kim","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"765","key":"10.1016\/j.phrs.2018.02.005_bib0100","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ejphar.2015.08.034","article-title":"Genetic variations of hOCT1 gene and CYP3A4\/A5 genes and their association with imatinib response in Chronic Myeloid Leukemia","volume":"765","author":"Vaidya","year":"2015","journal-title":"Eur. J. Pharmacol."},{"issue":"9","key":"10.1016\/j.phrs.2018.02.005_bib0105","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","article-title":"Clinical pharmacokinetics of imatinib","volume":"44","author":"Peng","year":"2005","journal-title":"Clin. Pharmacokinet."},{"issue":"9","key":"10.1016\/j.phrs.2018.02.005_bib0110","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/00008571-200112000-00005","article-title":"The genetic determinants of the CYP3A5 polymorphism","volume":"11","author":"Hustert","year":"2001","journal-title":"Pharmacogenetics"},{"issue":"9","key":"10.1016\/j.phrs.2018.02.005_bib0115","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.tig.2004.06.014","article-title":"Meta-analysis of genetic association studies","volume":"20","author":"Munafo","year":"2004","journal-title":"Trends Genet."},{"issue":"7","key":"10.1016\/j.phrs.2018.02.005_bib0120","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"issue":"9","key":"10.1016\/j.phrs.2018.02.005_bib0125","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J. Surg."},{"issue":"1","key":"10.1016\/j.phrs.2018.02.005_bib0130","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/ije\/31.1.72","article-title":"Can we individualize the number needed to treat? An empirical study of summary effect measures in meta-analyses","volume":"31","author":"Furukawa","year":"2002","journal-title":"Int. J. Epidemiol."},{"issue":"7","key":"10.1016\/j.phrs.2018.02.005_bib0135","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jclinepi.2007.12.011","article-title":"Synthesis of genetic association studies for pertinent genedisease associations requires appropriate methodological and statistical approaches","volume":"61","author":"Zintzaras","year":"2008","journal-title":"J. Clin. Epidemiol."},{"issue":"7414","key":"10.1016\/j.phrs.2018.02.005_bib0140","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"7109","key":"10.1016\/j.phrs.2018.02.005_bib0145","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.phrs.2018.02.005_bib0150","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1038\/leu.2010.188","article-title":"OCT-1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT-1","volume":"24","author":"White","year":"2010","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.phrs.2018.02.005_bib0155","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1093\/annonc\/mds532","article-title":"Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients","volume":"24","author":"Seong","year":"2013","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.phrs.2018.02.005_bib0160","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/bjh.12591","article-title":"A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia","volume":"163","author":"Grinfeld","year":"2013","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.phrs.2018.02.005_bib0165","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3324\/haematol.2012.066480","article-title":"Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy","volume":"98","author":"Angelini","year":"2013","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.phrs.2018.02.005_bib0170","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1007\/s12032-014-0851-5","article-title":"Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia","volume":"31","author":"de Lima","year":"2014","journal-title":"Med. Oncol."},{"issue":"8","key":"10.1016\/j.phrs.2018.02.005_bib0175","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s12032-015-0665-0","article-title":"Influence of Sokal, Hasford, EUTOS scores and pharmacogenetic factors on the complete cytogenetic response at 1\u2009year in chronic myeloid leukemia patients treated with imatinib","volume":"32","author":"Francis","year":"2015","journal-title":"Med. Oncol."},{"issue":"5","key":"10.1016\/j.phrs.2018.02.005_bib0180","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/jcpt.12424","article-title":"Influence of CYP3A5*3 and ABCB1 C3435T on clinical outcomes and trough plasma concentrations of imatinib in Nigerians with chronic myeloid leukaemia","volume":"41","author":"Adeagbo","year":"2016","journal-title":"J. Clin. Pharm. Ther."},{"issue":"2","key":"10.1016\/j.phrs.2018.02.005_bib0185","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s40487-016-0035-x","article-title":"Impact of CYP3A4*18 and CYP3A5*3 polymorphisms on imatinib mesylate response among chronic myeloid leukemia patients in Malaysia","volume":"4","author":"Maddin","year":"2016","journal-title":"Oncol. Ther."},{"key":"10.1016\/j.phrs.2018.02.005_bib0190","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.phrs.2017.03.011","article-title":"Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia","volume":"120","author":"Harivenkatesh","year":"2017","journal-title":"Pharmacol. Res."},{"issue":"17","key":"10.1016\/j.phrs.2018.02.005_bib0195","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.2217\/pgs-2016-0124","article-title":"Pharmacogenetics of drug transporters in modulating imatinib disposition and treatment outcomes in chronic myeloid leukemia & gastrointestinal stromal tumor patients","volume":"17","author":"Chen","year":"2016","journal-title":"Pharmacogenomics"},{"issue":"4","key":"10.1016\/j.phrs.2018.02.005_bib0200","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1159\/000336610","article-title":"Pretherapeutic expression of the hOCT1 gene predicts a complete molecular response to imatinib mesylate in chronic-phase chronic myeloid leukemia","volume":"127","author":"Nardinelli","year":"2012","journal-title":"Acta Haematol."},{"issue":"10","key":"10.1016\/j.phrs.2018.02.005_bib0205","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1038\/leu.2015.170","article-title":"OCT1 and imatinib transport in CML: is it clinically relevant?","volume":"29","author":"Watkins","year":"2015","journal-title":"Leukemia"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661817315232?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661817315232?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:56:40Z","timestamp":1760911000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661817315232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":41,"alternative-id":["S1043661817315232"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2018.02.005","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of SLC22A1 and CYP3A5 genotypes on imatinib response in chronic myeloid leukemia: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2018.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}